Latest news and press releases about Curis, Inc. (CRIS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Price
| Price | $1.12 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.48 |
| EV / EBITDA | 0.09 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -1035.26% |
| Return on Invested Capital | -567.17% |
| Return on Assets | -111.51% |
| Gross Margin | 99.28% |
| Operating Margin | -833.40% |
| Net Margin | -490.33% |
Related companies: ASBP · ATHA · BCTX · CTXR · ENTO · HOTH · ICU
Explore sector: Healthcare · Biotechnology
More sections of CRIS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks